Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials

Nadia Rosencher, Herbert Noack, Martin Feuring, Andreas Clemens, Richard J Friedman, Bengt I Eriksson, Nadia Rosencher, Herbert Noack, Martin Feuring, Andreas Clemens, Richard J Friedman, Bengt I Eriksson

Abstract

Background: There has been a shift towards greater use of neuraxial over general anaesthesia for patients undergoing total hip or knee arthroplasty. Furthermore, suggestions that peripheral nerve block may reduce adverse effects have recently been put forward. Although older studies showed a reduction in venous thromboembolism (VTE) with neuraxial compared with general anaesthesia, this difference has not been confirmed in studies using effective current thromboprophylaxis. We used a large data set to investigate the pattern of anaesthesia usage, and whether anaesthesia type affects efficacy and bleeding outcomes of thromboprophylaxis overall, within each treatment group, or for the novel oral anticoagulant dabigatran etexilate versus enoxaparin.

Methods: Three previously reported trials compared 220 mg and 150 mg dabigatran etexilate once daily with enoxaparin after knee or hip arthroplasty. A pooled analysis was performed in patients receiving general or neuraxial anaesthesia, or the combination of either with peripheral nerve block (n = 8062). Outcome measures were major VTE plus VTE-related mortality, major bleeding and major plus clinically relevant bleeding events.

Results: General, neuraxial and combination anaesthesia were used in 29%, 52% and 19% of patients, respectively. Differences in efficacy and safety between anaesthesia subgroups were small and not significant, except for a slightly higher rate of major VTE and VTE-related mortality with general versus neuraxial anaesthesia (odds ratio: 1.40; 95% confidence interval: 1.03-1.90; p = 0.035) in the overall population. There were no significant effects of anaesthesia type on efficacy or safety of dabigatran etexilate versus enoxaparin.

Conclusions: Anaesthesia type did not greatly affect efficacy and safety outcomes in the pooled population of all three treatment groups. The efficacy and safety of dabigatran etexilate was comparable with enoxaparin, regardless of type of anaesthesia.

Trial registration: ClinicalTrials.gov identifiers: NCT00168805, NCT00168818, NCT00152971.

Figures

Figure 1
Figure 1
Flow diagram showing patients comprising the pooled safety population in this post-hoc analysis.
Figure 2
Figure 2
Comparison of 220 mg and 150 mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia: (A) major venous thromboembolism (VTE) and VTE-related mortality; (B) major bleeding events; (C) major bleeding events plus clinically relevant bleeding events. Data are presented as the odds ratio with 95% confidence intervals.

References

    1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA. et al.Prevention of venous thromboembolism. Chest. 2001;119:132S–175S. doi: 10.1378/chest.119.1_suppl.132S.
    1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. et al.Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:381S–453S. doi: 10.1378/chest.08-0656.
    1. Rosencher N. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations. Anaesthesia. 2004;59:803–810. doi: 10.1111/j.1365-2044.2004.03840.x.
    1. European Public Assessment Report. European Medicines Agency. 2012. [ ] Accessed January 23.
    1. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP. et al.Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185. doi: 10.1111/j.1538-7836.2007.02748.x.
    1. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP. et al.Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–956. doi: 10.1016/S0140-6736(07)61445-7.
    1. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH. et al.Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.
    1. Anderson FA, Hirsh J, White K, Fitzgerald RH. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest. 2003;124:349S–356S. doi: 10.1378/chest.124.6_suppl.349S.
    1. Nicholls B. Lower limb nerve blocks. Anaesthesia. 2010;11:105–108.
    1. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia. 2007;62:1154–1160. doi: 10.1111/j.1365-2044.2007.05195.x.
    1. Macfarlane AJ, Prasad GA, Chan VW, Brull R. Does regional anaesthesia improve outcome after total hip arthroplasty? A systematic review. Br J Anaesth. 2009;103:335–345. doi: 10.1093/bja/aep208.
    1. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk (effective May 31, 2008) CPMP/EWP/707/98 Rev. 1. European Medicines Agency. 2012. [ ] Accessed January 23.
    1. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML. et al.A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–111. doi: 10.1111/j.1538-7836.2004.01100.x.
    1. Chelly JE, Greger J, Gebhard R, Coupe K, Clyburn TA, Buckle R. et al.Continuous femoral blocks improve recovery and outcome of patients undergoing total knee arthroplasty. J Arthroplasty. 2001;16:436–445. doi: 10.1054/arth.2001.23622.
    1. Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2008;100:154–164.
    1. Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005;3:2006–2014. doi: 10.1111/j.1538-7836.2005.01545.x.
    1. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest. 2003;124:371S–378S. doi: 10.1378/chest.124.6_suppl.371S.
    1. Modig J. The role of lumbar epidural anaesthesia as antithrombotic prophylaxis in total hip replacement. Acta Chir Scand. 1985;151:589–594.
    1. Prins MH, Hirsh J. A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. Thromb Haemost. 1990;64:497–500.
    1. Samama CM, Barre J, Clergue F, Samii K. [Benefits of regional anesthesia. Anticoagulant treatment and regional anesthesia] Ann Fr Anesth Reanim. 1992;11:282–287. doi: 10.1016/S0750-7658(05)80360-0.
    1. O'Hara DA, Duff A, Berlin JA, Poses RM, Lawrence VA, Huber EC. et al.The effect of anesthetic technique on postoperative outcomes in hip fracture repair. Anesthesiology. 2000;92:947–957. doi: 10.1097/00000542-200004000-00011.
    1. Rodgers A, Walker N, Schug S, McKee A, Kehlet H, Van ZA. et al.Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ. 2000;321:1493. doi: 10.1136/bmj.321.7275.1493.
    1. Sorenson RM, Pace NL. Anesthetic techniques during surgical repair of femoral neck fractures. A meta-analysis. Anesthesiology. 1992;77:1095–1104. doi: 10.1097/00000542-199212000-00009.
    1. Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anaesth. 2000;84:450–455. doi: 10.1093/oxfordjournals.bja.a013468.
    1. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW. et al.Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010;126:175–182. doi: 10.1016/j.thromres.2010.03.021.
    1. Manoir BD, Bourget P, Langlois M, Szekely B, Fischler M, Chauvin M. et al.Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty. Eur J Anaesthesiol. 2006;23:748–754. doi: 10.1017/S0265021506000731.
    1. Dahl OE, Kurth AA, Rosencher N, Schnee JM, Clemens A, Hantel S. et al.Delay in initiating prophylactic treatment with dabigatran etxilate following total hip or knee replacement surgery did not affect efficacy. Pooled analysis of two European phase III trials [abstract] J Thromb Haemost. 2009;7(Suppl):695.
    1. Dahl OE, Kurth AA, Rosencher N, Noack H, Clemens A, Eriksson BI. Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing hip or knee replacement. Int Orthop. 2011;36:741–748.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅